HPV16 seropositivity relatively common prior to diagnosis of anal cancer
the ONA take:
According to a new study published online in the Journal of Clinical Oncology, researchers from the National Cancer Institute in Bethesda, Maryland, have found that human papillomavirus (HPV) type 16 (HPV16) seropositivity is relatively common in people prior to receiving a diagnosis of anal cancer.
Because the European Prospective Investigation Into Cancer and Nutrition Study found that HPV16 E6 seropositivity was present in people more than 10 years prior to being diagnosed with oropharyngeal cancer, researchers sought to investigate the extent to which HPV16 E6 seropositivity was present before the diagnosis of anogenital cancers.
Researchers identified 400 cases of anogenital cancers and 718 matched control in which prediagnostic blood samples were available. Results showed that 29.2% of those who later developed anal cancer had HPV16 E6 seropositivity compared with 0.6% of controls (OR = 75.9).
HPV16 E6 seropositivity was less common in patients who later developed cervical, penilee, vaginal, and vulvar cancers. HPV16 E6 seropositivity was more common in blood samples drawn closer in time to diagnosis.
HPV16 seropositivity is relatively common in people prior to receiving a diagnosis of anal cancer.
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- Refined Equation May Obviate Oncotype DX in Breast Cancer Treatment Decisions
- Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis
- Intermediate Oncotype DX Scores Prognostic of OS in Early-stage Breast Cancer
- Colorectal Cancer and Dietary Fiber: Source Is More Important Than Amount
- Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|